MCID: DBT006
MIFTS: 48

Diabetic Macular Edema

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Diabetic Macular Edema

MalaCards integrated aliases for Diabetic Macular Edema:

Name: Diabetic Macular Edema 12 54 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9191
ICD9CM 34 362.07
SNOMED-CT 67 312912001
UMLS 71 C0730285

Summaries for Diabetic Macular Edema

MalaCards based summary : Diabetic Macular Edema is related to macular retinal edema and endophthalmitis. An important gene associated with Diabetic Macular Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Diclofenac and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Diabetic Macular Edema

Diseases related to Diabetic Macular Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 32.4 VEGFA SERPINF1 PRKCB IL6 ICAM1 CCL2
2 endophthalmitis 31.9 VEGFA IL6 ICAM1
3 background diabetic retinopathy 31.6 VEGFA IL6 ICAM1 AKR1B1
4 macular holes 31.5 VEGFA SERPINF1 CCL2
5 retinal detachment 31.4 VEGFA SERPINF1 IL6 FGF2 EPO CCL2
6 retinal vein occlusion 31.3 VEGFA SERPINF1 IL6 CCL2
7 retinal microaneurysm 31.3 VEGFA REN AKR1B1
8 kuhnt-junius degeneration 31.3 VEGFC VEGFA TEK
9 central retinal vein occlusion 31.1 VEGFA SERPINF1 IL6
10 uveitis 31.0 SERPINF1 IL6 ICAM1 CCL2
11 retinal ischemia 31.0 VEGFA ICAM1 HIF1A FGF2
12 microvascular complications of diabetes 5 30.9 VEGFA TEK SOD2 SERPINF1 PRKCB NOS3
13 severe nonproliferative diabetic retinopathy 30.8 VEGFA REN PRKCB ICAM1 CCL2 AKR1B1
14 retinal artery occlusion 30.7 VEGFA IL6 ICAM1 CCL2
15 macular dystrophy, dominant cystoid 30.7 VEGFA SERPINF1 PRKCB
16 microvascular complications of diabetes 1 30.6 VEGFA SST SERPINF1 PRKCB ICAM1 HIF1A
17 leukostasis 30.5 VEGFA SERPINF1 IL6 ICAM1 CCL2
18 cataract 30.5 VEGFA SOD2 SERPINF1 IL6 ICAM1 HIF1A
19 macular degeneration, age-related, 1 30.4 VEGFC VEGFA TEK SERPINF1 IL6 ICAM1
20 retinal vascular occlusion 30.3 VEGFA SERPINF1 IL6 ICAM1 CCL2
21 hyperglycemia 30.2 SST SOD2 PRKCB NOS3 IL6 HIF1A
22 peripheral vascular disease 30.1 VEGFA NOS3 IL6 EPO CCL2
23 chronic kidney disease 30.1 VEGFA REN NOS3 IL6 EPO CCL2
24 apnea, obstructive sleep 30.0 VEGFA REN NOS3 IL6 HIF1A
25 vascular disease 29.9 VEGFA TEK REN NOS3 IL6 ICAM1
26 transient cerebral ischemia 29.9 SOD2 HSPA5 CCL2
27 ischemia 29.8 VEGFA TEK SOD2 NOS3 ICAM1 HIF1A
28 retinal vascular disease 29.8 VEGFA TEK SERPINF1 REN NOS3 IL6
29 sleep apnea 29.7 VEGFA REN NOS3 IL6 ICAM1 HIF1A
30 eye disease 29.7 VEGFA SST SERPINF1 PRKCB IL6 ICAM1
31 end stage renal disease 29.7 VEGFA SOD2 REN NOS3 IL6 EPO
32 glioblastoma multiforme 29.6 VEGFA PRKCB IL6 ICAM1 HSPA5 HIF1A
33 diabetic neuropathy 29.5 VEGFA SOD2 REN PRKCB ICAM1 FGF2
34 myocardial infarction 28.9 VEGFA TEK REN NOS3 IL6 ICAM1
35 retinitis pigmentosa 28.8 VEGFA SOD2 SERPINF1 IL6 HSPA5 HIF1A
36 diabetes mellitus, type i 28.7 VEGFA SST SOD2 REN PRKCB NOS3
37 diabetes mellitus 28.6 VEGFA SST SOD2 REN PRKCB NOS3
38 diabetes mellitus, noninsulin-dependent 28.3 VEGFA SST REN PRKCB NOS3 IL6
39 hypertension, essential 27.7 VEGFC VEGFA TEK SST SOD2 REN
40 microvascular complications of diabetes 2 10.9
41 yemenite deaf-blind hypopigmentation syndrome 10.8
42 vitreous detachment 10.7
43 retinal disease 10.6
44 vibrio vulnificus infection 10.6 IL6 EPO
45 ocular hypertension 10.6
46 cytokine deficiency 10.5
47 hemifacial spasm 10.5 VEGFA NOS3
48 familial glomangioma 10.5 TEK FGF2
49 intravascular papillary endothelial hyperplasia 10.5 VEGFA HIF1A
50 eales disease 10.5 VEGFA SERPINF1 IL6

Graphical network of the top 20 diseases related to Diabetic Macular Edema:



Diseases related to Diabetic Macular Edema

Symptoms & Phenotypes for Diabetic Macular Edema

MGI Mouse Phenotypes related to Diabetic Macular Edema:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ANGPTL4 EPO FGF2 HIF1A HSPA5 ICAM1
2 homeostasis/metabolism MP:0005376 10.39 AKR1B1 ANGPTL4 CASP14 EPO FGF2 HIF1A
3 hematopoietic system MP:0005397 10.3 ANGPTL4 EPO FGF2 HIF1A HPX ICAM1
4 immune system MP:0005387 10.28 ANGPTL4 CCL2 EPO HIF1A HPX ICAM1
5 mortality/aging MP:0010768 10.27 AKR1B1 ANGPTL4 EPO FGF2 HIF1A HPX
6 growth/size/body region MP:0005378 10.26 AKR1B1 ANGPTL4 HIF1A HSPA5 ICAM1 IL6
7 digestive/alimentary MP:0005381 10.15 ANGPTL4 HIF1A HSPA5 ICAM1 IL6 NOS3
8 muscle MP:0005369 10.02 EPO FGF2 HIF1A ICAM1 IL6 NOS3
9 nervous system MP:0003631 10 ANGPTL4 FGF2 HIF1A HSPA5 ICAM1 IL6
10 neoplasm MP:0002006 9.8 FGF2 HIF1A HSPA5 ICAM1 IL6 SOD2
11 renal/urinary system MP:0005367 9.61 AKR1B1 HIF1A HPX HSPA5 IL6 NOS3
12 vision/eye MP:0005391 9.36 AKR1B1 ANGPTL4 FGF2 HIF1A ICAM1 IL6

Drugs & Therapeutics for Diabetic Macular Edema

Drugs for Diabetic Macular Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
4
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Bromfenac Approved Phase 4 91714-94-2 60726
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
9
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
10
Homatropine Approved Phase 4 87-00-3
11
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
12
Verteporfin Approved, Investigational Phase 4 129497-78-5
13
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
14
Empagliflozin Approved Phase 4 864070-44-0
15
Glimepiride Approved Phase 4 93479-97-1 3476
16
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
17 Antineoplastic Agents, Hormonal Phase 4
18 Antiemetics Phase 4
19 BB 1101 Phase 4
20 Dipeptidyl-Peptidase IV Inhibitors Phase 4
21 Cardiac Glycosides Phase 4
22 Glycoside Hydrolase Inhibitors Phase 4
23 Mitogens Phase 4
24 Endothelial Growth Factors Phase 4
25 Cyclooxygenase Inhibitors Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Analgesics Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Norgestimate, ethinyl estradiol drug combination Phase 4
30 Ketorolac Tromethamine Phase 4
31 Photosensitizing Agents Phase 4
32
protease inhibitors Phase 4
33 HIV Protease Inhibitors Phase 4
34 Anti-Arrhythmia Agents Phase 4
35 Immunologic Factors Phase 4
36 Immunosuppressive Agents Phase 4
37 Insulin, Globin Zinc Phase 4
38 insulin Phase 4
39 Hypoglycemic Agents Phase 4
40 Sodium-Glucose Transporter 2 Inhibitors Phase 4
41
Temazepam Approved, Investigational Phase 3 846-50-4 5391
42
Danazol Approved Phase 3 17230-88-5 28417
43
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
44
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
45
Povidone-iodine Approved Phase 3 25655-41-8
46
Iodine Approved, Investigational Phase 3 7553-56-2 807
47
Povidone Approved Phase 3 9003-39-8
48
Infliximab Approved Phase 3 170277-31-3
49
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
50
Insulin aspart Approved Phase 2, Phase 3 116094-23-6 16132418

Interventional clinical trials:

(show top 50) (show all 507)
# Name Status NCT ID Phase Drugs
1 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
2 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
3 The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor Unknown status NCT03475407 Phase 4 Ozurdex intravitreal injection
4 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
5 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
6 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
7 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
8 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
9 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
10 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
11 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
12 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
13 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
14 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
15 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
16 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
17 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
18 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
19 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
20 A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
21 Central Macular Thickness, Macular Electroretinogram, and Visual Acuity in Patients With Diabetic Macular Edema After Intravitreal Aflibercept Injection. A One Month Pre-Post Intervention Follow Up Study Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
22 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
23 A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
24 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
25 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
26 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Treatment Naïve Patients With Diabetic Macular Edema Completed NCT02441907 Phase 4 aflibercept
27 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
28 Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
29 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
30 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
31 Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema Completed NCT04087746 Phase 4 Aflibercept;Ranibizumab
32 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
33 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
34 Ranibizumab and Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema Completed NCT04089605 Phase 4 dexamethasone implant;Ranibizumab
35 Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
36 Aflibercept With Adjuvant Micro-Pulsed Yellow Laser Versus Aflibercept Monotherapy in Treatment of Diabetic Macular Edema. Completed NCT03866746 Phase 4 Aflibercept Injection
37 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
38 A 12-months, Randomized, VA-assessor Blinded, Multicenter, Controlled Phase IV Trial to Investigate Noninferiority of Two Treatment Algorithms (Discretion of the Investigator vs. Pro re Nata) of 0.5 mg Ranibizumab in Patients With Visual Impairment Due to Diabetic Macula Edema Completed NCT02366468 Phase 4 ranibizumab 0.5 mg
39 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
40 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
41 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
42 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 1 Trial) Completed NCT02297204 Phase 4 aflibercept 2.0 mg
43 Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab Completed NCT03340610 Phase 4 Alflibercept
44 A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema Completed NCT02633852 Phase 4 Aflibercept
45 Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial Completed NCT02734407 Phase 4 aflibercept 2.0 mg
46 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
47 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
48 Yellow Micropulse Laser 577-nm vs Infrared Diode Micropulse Laser 810-nm for the Treatment of Diabetic Macular Edema Completed NCT04359771 Phase 4
49 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4 Ketorolac
50 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab

Search NIH Clinical Center for Diabetic Macular Edema

Genetic Tests for Diabetic Macular Edema

Anatomical Context for Diabetic Macular Edema

MalaCards organs/tissues related to Diabetic Macular Edema:

40
Eye, Endothelial, Retina, Testes, Bone, Monocytes, Cortex

Publications for Diabetic Macular Edema

Articles related to Diabetic Macular Edema:

(show top 50) (show all 3323)
# Title Authors PMID Year
1
Update on treatments of diabetic macular edema. 61 54
19951615 2009
2
Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. 61 54
19060271 2009
3
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. 61 54
19381089 2009
4
Treating diabetic retinopathy by inhibiting growth factor pathways. 61 54
19337953 2009
5
Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. 61 54
18328456 2008
6
Spontaneous resolution of vitreomacular traction following ranibizumab (Lucentis) injection. 54 61
18320528 2008
7
Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. 61 54
17505145 2007
8
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. 54 61
17245083 2007
9
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. 54 61
17046701 2006
10
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. 54 61
16406543 2006
11
Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. 61 54
16186374 2005
12
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. 54 61
15963467 2005
13
Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. 54 61
15878060 2005
14
Pharmacotherapy for diabetic retinopathy. 61 54
15523197 2004
15
Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. 54 61
15096582 2004
16
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. 61 54
13129863 2003
17
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. 54 61
12652651 2003
18
Relation of diabetic macular edema to cytokines and posterior vitreous detachment. 61 54
12614749 2003
19
[The influence of spontaneous posterior vitreous detachment in resolution of diabetic macular edema in NIDDM]. 61 54
15049255 2003
20
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. 61 54
11931788 2002
21
Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. 61 54
11755841 2002
22
Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. 61 54
11530050 2001
23
New surgical approach for removing massive foveal hard exudates in diabetic macular edema. 61 54
9951473 1999
24
Scleral fixation of fluocinolone acetonide implant. 61
32577584 2020
25
Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia. 61
32114640 2020
26
Feelings, preoperative anxiety, and need for information in patients undergoing intravitreal injections. 61
32346786 2020
27
Fundamental principles of an effective diabetic retinopathy screening program. 61
32222818 2020
28
Real-world Outcomes among Eyes with Center-Involving Diabetic Macular Edema and Good Visual Acuity. 61
31829753 2020
29
Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management. 61
32209341 2020
30
NONCONFOCAL ULTRA-WIDEFIELD SCANNING LASER OPHTHALMOSCOPY: Polarization Artifacts and Diabetic Macular Edema. 61
31181039 2020
31
Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. 61
31570814 2020
32
SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. 61
31356494 2020
33
Diabetic Eye Disease: Advancements in Technology, Detection, and Access to Care. 61
32456756 2020
34
Macular and Peripapillary OCTA Metrics Predict Progression in Diabetic Retinopathy: A Sub-analysis of TIME-2b Study Data. 61
32574773 2020
35
Performance of deep neural network-based artificial intelligence method in diabetic retinopathy screening: a systematic review and meta-analysis of diagnostic test accuracy. 61
32504495 2020
36
Diabetic Macular Edema: State of Art and Intraocular Pharmacological Approaches. 61
32488606 2020
37
Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China. 61
32539744 2020
38
INVICTUS: Intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: A 12 months follow-up study. 61
32507032 2020
39
The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema. 61
32560526 2020
40
Retinal layers changes in patients with diabetic macular edema treated with intravitreal anti-VEGF agents: Long-term outcomes of a spectral-domain OCT study. 61
32564022 2020
41
Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial. 61
32542431 2020
42
[Treatment adherence and effectiveness of anti-Vascular Endothelial Growth Faktor(VEGF) treatment of diabetic macular edema in the clinical routine : Comparison between cooperative and unicentric organization of treatment]. 61
31555836 2020
43
Dexamethasone intravitreal implant in the crystalline lens: a case report. 61
32490981 2020
44
A Novelty Route for Smartphone-based Artificial Intelligence Approach to Ophthalmic Screening. 61
32520771 2020
45
Spectral domain optical coherence tomography classification of diabetic macular edema: a new proposal to clinical practice. 61
32152718 2020
46
COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT. 61
30950970 2020
47
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. 61
31567817 2020
48
Joint Diabetic Macular Edema Segmentation and Characterization in OCT Images. 61
32562127 2020
49
Statin reduces the incidence of diabetic retinopathy and its need for intervention: A systematic review and meta-analysis. 61
32530705 2020
50
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy. 61
32356244 2020

Variations for Diabetic Macular Edema

Expression for Diabetic Macular Edema

Search GEO for disease gene expression data for Diabetic Macular Edema.

Pathways for Diabetic Macular Edema

Pathways related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 VEGFC VEGFA TEK IL6 ICAM1 FGF2
2
Show member pathways
13.34 VEGFA TEK IL6 ICAM1 HIF1A FGF2
3
Show member pathways
13.25 VEGFC VEGFA TEK PRKCB NOS3 IL6
4
Show member pathways
13.11 VEGFA SOD2 IL6 HSPA5 HIF1A EPO
5
Show member pathways
12.99 VEGFC REN PRKCB IL6 HIF1A FGF2
6
Show member pathways
12.9 VEGFC VEGFA TEK NOS3 IL6 FGF2
7
Show member pathways
12.85 VEGFA PRKCB IL6 ICAM1 HIF1A FGF2
8 12.76 VEGFC VEGFA PRKCB IL6 HIF1A FGF2
9
Show member pathways
12.72 VEGFC VEGFA TEK PRKCB FGF2
10 12.69 VEGFC VEGFA TEK PRKCB HSPA5 FGF2
11
Show member pathways
12.64 VEGFC VEGFA SST PRKCB NOS3
12
Show member pathways
12.62 VEGFA PRKCB NOS3 ICAM1 CCL2
13
Show member pathways
12.57 VEGFA PRKCB IL6 HIF1A FGF2
14
Show member pathways
12.54 TEK NOS3 IL6 FGF2 CCL2
15
Show member pathways
12.42 VEGFC VEGFA PRKCB NOS3 FGF2 CASP14
16
Show member pathways
12.34 VEGFA PRKCB NOS3 ICAM1 CCL2
17
Show member pathways
12.31 SOD2 IL6 ICAM1 CCL2
18 12.28 VEGFA PRKCB HIF1A FGF2
19
Show member pathways
12.27 VEGFA PRKCB HIF1A CCL2
20 12.13 VEGFA SST IL6 HIF1A
21 12.05 VEGFA NOS3 ICAM1 CCL2
22 11.93 VEGFC IL6 ICAM1 CCL2
23 11.86 VEGFA IL6 ICAM1 HIF1A FGF2 CCL2
24
Show member pathways
11.8 VEGFC VEGFA NOS3 HIF1A
25 11.77 VEGFA TEK IL6 ICAM1 CCL2
26 11.74 VEGFA TEK PRKCB NOS3 IL6 HIF1A
27 11.67 PRKCB NOS3 HIF1A
28 11.66 VEGFA HIF1A EPO
29
Show member pathways
11.64 VEGFA IL6 ICAM1
30 11.63 IL6 FGF2 CCL2
31 11.52 VEGFA IL6 HIF1A
32 11.51 IL6 ICAM1 CCL2
33 11.5 VEGFC VEGFA NOS3 HIF1A EPO
34 11.5 VEGFC VEGFA PRKCB NOS3 IL6 ICAM1
35 11.49 IL6 ICAM1 CCL2
36 11.44 VEGFA IL6 FGF2 EPO
37 11.34 VEGFA HIF1A EPO
38 11.34 PRKCB IL6 ICAM1
39 11.29 NOS3 IL6 CCL2
40 11.12 VEGFC TEK REN NOS3 HIF1A FGF2
41 11.03 VEGFA TEK NOS3 HIF1A FGF2
42 10.56 VEGFC VEGFA HIF1A

GO Terms for Diabetic Macular Edema

Cellular components related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.81 SERPINF1 PRKCB NOS3 IL6 ICAM1 HPX
2 extracellular region GO:0005576 9.73 VEGFC VEGFA TEK SST SERPINF1 REN
3 extracellular space GO:0005615 9.44 VEGFC VEGFA SST SERPINF1 REN IL6

Biological processes related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.22 VEGFC VEGFA TEK PRKCB IL6 HIF1A
2 negative regulation of apoptotic process GO:0043066 9.97 VEGFA TEK IL6 HSPA5 HIF1A EPO
3 positive regulation of cell migration GO:0030335 9.92 VEGFC VEGFA SOD2 HSPA5
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 TEK ICAM1 FGF2 EPO CCL2
5 cytokine-mediated signaling pathway GO:0019221 9.88 VEGFA IL6 ICAM1 HIF1A FGF2 CCL2
6 response to lipopolysaccharide GO:0032496 9.86 REN NOS3 ICAM1 EPO
7 response to organic substance GO:0010033 9.81 TEK REN AKR1B1
8 cellular response to interleukin-1 GO:0071347 9.8 ICAM1 HIF1A CCL2
9 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.79 VEGFA HIF1A EPO
10 regulation of blood pressure GO:0008217 9.77 SOD2 REN NOS3
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 VEGFA IL6 HPX EPO
12 positive chemotaxis GO:0050918 9.72 VEGFC VEGFA FGF2
13 positive regulation of endothelial cell proliferation GO:0001938 9.72 VEGFC VEGFA TEK HIF1A FGF2
14 positive regulation of cell division GO:0051781 9.71 VEGFC VEGFA FGF2
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.7 TEK ICAM1 ANGPTL4
16 response to hypoxia GO:0001666 9.7 VEGFC VEGFA TEK ICAM1 HIF1A EPO
17 sprouting angiogenesis GO:0002040 9.69 VEGFC VEGFA TEK
18 positive regulation of neuroblast proliferation GO:0002052 9.67 VEGFC VEGFA HIF1A
19 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 VEGFC VEGFA NOS3 HIF1A FGF2
20 removal of superoxide radicals GO:0019430 9.63 SOD2 NOS3
21 PERK-mediated unfolded protein response GO:0036499 9.63 HSPA5 CCL2
22 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.63 VEGFA PRKCB HIF1A
23 oxygen homeostasis GO:0032364 9.61 SOD2 HIF1A
24 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.59 VEGFA HIF1A
25 positive regulation of mast cell chemotaxis GO:0060754 9.58 VEGFC VEGFA
26 hemoglobin biosynthetic process GO:0042541 9.58 HIF1A EPO
27 angiogenesis GO:0001525 9.56 VEGFC VEGFA TEK NOS3 HIF1A FGF2
28 positive regulation of angiogenesis GO:0045766 9.23 VEGFC VEGFA TEK PRKCB NOS3 HIF1A

Molecular functions related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 VEGFC VEGFA IL6 FGF2
2 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFC VEGFA
3 chemoattractant activity GO:0042056 9.13 VEGFC VEGFA FGF2
4 cytokine activity GO:0005125 9.02 VEGFA IL6 FGF2 EPO CCL2

Sources for Diabetic Macular Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....